Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
Chimeric antigen receptor T-cell (CAR-T) therapy is a form of immunotherapy that harnesses the power of the patient's own immune system to combat cancer. This innovative treatment involves the extraction of the patient's white blood cells, specifically lymphocytic T-cells, which play a crucial role in the immune response. The process begins with the collection of these T-cells from the patient's blood, which may take place over one or more days. Once collected, the T-cells are genetically modified in a laboratory setting using a disarmed virus. This virus is engineered to introduce specific genetic material into the T-cells, enabling them to produce chimeric antigen receptors (CARs) on their surface. These CARs are designed to recognize and bind to particular protein antigens found on the surface of cancer cells, thereby enhancing the T-cells' ability to identify and attack malignant cells. After the T-cells have been successfully modified to express CARs, they are expanded and multiplied to create a substantial population, often numbering in the hundreds of millions. Concurrently, the patient undergoes lymphocytic cell-depleting chemotherapy to prepare their immune system for the subsequent infusion of the engineered T-cells. Once the CAR-T cells are ready and the patient is adequately prepared, the modified T-cells are infused back into the patient's bloodstream. Upon reintroduction, these CAR-T cells seek out and bind to the cancer cells, initiating a targeted immune response that leads to the destruction of the cancerous cells. The CAR-T cells can persist in the body for an extended period, providing ongoing surveillance and defense against potential cancer recurrence.
© Copyright 2026 Coding Ahead. All rights reserved.
The indications for CAR-T therapy are primarily focused on specific types of cancers where traditional treatments may be less effective. This therapy is typically indicated for patients with:
The procedure for CAR-T therapy involves several critical steps that ensure the effective modification and reinfusion of the patient's T-cells. The steps are as follows:
After the CAR-T cell infusion, patients are closely monitored for any potential side effects and complications, which can include cytokine release syndrome (CRS) and neurological effects. The duration of monitoring may vary based on the patient's response and any adverse reactions. Patients may also require supportive care to manage symptoms and ensure recovery. The CAR-T cells can remain active in the body for an extended period, providing ongoing surveillance against cancer recurrence. Follow-up appointments are essential to assess the effectiveness of the therapy and to monitor the patient's overall health and response to treatment.
| Short Descr | CAR-T CLL ADMN AUTOLOGOUS | Medium Descr | CAR-T THERAPY AUTOLOGOUS CELL ADMINISTRATION | Long Descr | Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous | Status Code | Carriers Price the Code | Global Days | YYY - Carrier Determines Whether Global Concept Applies | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Procedure or Service, Not Discounted when Multiple | Berenson-Eggers TOS (BETOS) | none | MUE | Not applicable/unspecified. |
| KX | Requirements specified in the medical policy have been met | Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study | 58 | Staged or related procedure or service by the same physician or other qualified health care professional during the postoperative period: it may be necessary to indicate that the performance of a procedure or service during the postoperative period was: (a) planned or anticipated (staged); (b) more extensive than the original procedure; or (c) for therapy following a surgical procedure. this circumstance may be reported by adding modifier 58 to the staged or related procedure. note: for treatment of a problem that requires a return to the operating/procedure room (eg, unanticipated clinical condition), see modifier 78. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 76 | Repeat procedure or service by same physician or other qualified health care professional: it may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 76 to the repeated procedure or service. note: this modifier should not be appended to an e/m service. | AQ | Physician providing a service in an unlisted health professional shortage area (hpsa) | FS | Split (or shared) evaluation and management visit | GC | This service has been performed in part by a resident under the direction of a teaching physician | GZ | Item or service expected to be denied as not reasonable and necessary | KY | Dmepos item subject to dmepos competitive bidding program number 5 | LU | Fractionated payment | Q0 | Investigational clinical service provided in a clinical research study that is in an approved clinical research study | SA | Nurse practitioner rendering service in collaboration with a physician | XP | Separate practitioner, a service that is distinct because it was performed by a different practitioner |
Get instant expert-level medical coding assistance.